-
公开(公告)号：US20070249702A1
公开(公告)日：2007-10-25
申请号：US11668966
申请日：2007-01-30
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： A61K31/135 , A61K31/18 , A61K31/357 , A61K31/404 , A61P43/00 , C07C211/03 , C07C307/02 , C07D209/04 , C07D317/46
CPC分类号： C07D209/43 , C07B2200/07 , C07C217/60 , C07C255/46 , C07C311/29 , C07C323/25 , C07C2601/14 , C07C2603/74 , C07D317/54 , C07D317/64
摘要： The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得另外的钙化合物的技术。
-
公开(公告)号：US07202261B2
公开(公告)日：2007-04-10
申请号：US10896614
申请日：2004-07-21
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： A01N43/40
CPC分类号： A61K31/137 , A61K31/18 , A61K31/277
摘要： The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得另外的钙化合物的技术。
-
公开(公告)号：US06818660B2
公开(公告)日：2004-11-16
申请号：US10033001
申请日：2001-10-19
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： A61K31135
CPC分类号： C07C323/25 , A61K31/137 , A61K31/18 , A61K31/277 , C07C217/30 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C2601/14 , C07C2603/74 , C07D213/65 , C07D317/58 , C07D333/70
摘要： The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得另外的钙化合物的技术。
-
公开(公告)号：US06521667B1
公开(公告)日：2003-02-18
申请号：US09132179
申请日：1998-08-11
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： A01N3302
CPC分类号： C07C311/29 , A61K31/137 , A61K31/18 , A61K31/277 , C07C217/30 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C323/25 , C07C2601/14 , C07C2603/74 , C07D213/65 , C07D317/58 , C07D333/70
摘要： The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
-
公开(公告)号：US06432656B1
公开(公告)日：2002-08-13
申请号：US09370097
申请日：1999-08-06
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： G01N33554
CPC分类号： A61K31/137 , A61K31/18 , A61K31/277 , C07C217/30 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C323/25 , C07C2601/14 , C07C2603/74 , C07D213/65 , C07D317/58 , C07D333/70 , Y10S435/96 , Y10S436/811 , Y10S436/815
摘要： The present invention features calcilytic compounds. “calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得另外的钙化合物的技术。
-
公开(公告)号：US6022894A
公开(公告)日：2000-02-08
申请号：US832984
申请日：1997-04-04
申请人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
发明人： Eric G. Del Mar , Robert M. Barmore , Derek Sheehan , Bradford C. Van Wagenen , James F. Callahan , Richard M. Keenan , Nikesh R. Kotecha , Maria Amparo Lago , Linda Sue Southall , Mervyn Thompson
IPC分类号： G01N33/50 , A61K31/13 , A61K31/135 , A61K31/137 , A61K31/18 , A61K31/277 , A61K31/36 , A61K31/395 , A61K31/404 , A61P19/00 , A61P19/08 , A61P19/10 , C07C217/14 , C07C217/28 , C07C217/30 , C07C217/34 , C07C217/38 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C311/29 , C07C323/25 , C07D209/42 , C07D213/65 , C07D317/58 , C07D317/64 , C07D333/70 , G01N33/15
CPC分类号： C07C311/29 , A61K31/137 , A61K31/18 , A61K31/277 , C07C217/30 , C07C217/60 , C07C217/62 , C07C255/46 , C07C255/54 , C07C323/25 , C07D213/65 , C07D317/58 , C07D333/70 , C07C2101/14 , C07C2103/74
摘要： The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
摘要翻译： 本发明具有钙化合物。 “钙化合物”是指能够抑制钙受体活性的化合物。 还描述了使用钙化合物抑制钙受体活性和/或在患者中获得有益效果; 以及可用于获得另外的钙化合物的技术。
-
公开(公告)号：US07629350B2
公开(公告)日：2009-12-08
申请号：US10511770
申请日：2003-04-18
IPC分类号： A61K31/517 , C07D471/04 , C07D239/02
CPC分类号： C07D471/04
摘要： Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
摘要翻译： 新型取代的2,4,8-三取代-8H-吡啶并[2,3-d]嘧啶-7-酮化合物和用作CSBP / p38激酶抑制剂治疗的组合物。
-
公开(公告)号：US06864267B2
公开(公告)日：2005-03-08
申请号：US10333096
申请日：2001-07-16
IPC分类号： A61K31/4436 , C07D213/80 , C07D213/84 , C07D409/12 , C07D409/02
CPC分类号： C07D213/80 , A61K31/4436 , C07D213/84 , C07D409/12 , A61K2300/00
摘要： Novel calcilytic compounds and methods of using them are provided.
摘要翻译： 提供新的钙质化合物及其使用方法。
-
公开(公告)号：US20090239846A1
公开(公告)日：2009-09-24
申请号：US11908435
申请日：2006-03-24
申请人： James F. Callahan , Zehong Wan , Hongxing Yan , Xichen Lin
发明人： James F. Callahan , Zehong Wan , Hongxing Yan , Xichen Lin
IPC分类号： A61K31/551 , A61K31/5377 , A61K31/519 , C07D243/08 , C07D413/00 , C07D487/04
CPC分类号： C07D487/04
摘要： Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
摘要翻译： 新型取代的1,5,7-三取代-3,4-二氢嘧啶并[4,5-d]嘧啶-2-（1H） - 酮化合物及其组合物及其在CSBP / RK / p38激酶抑制剂治疗中的用途 。
-
公开(公告)号：US20090156597A1
公开(公告)日：2009-06-18
申请号：US12132793
申请日：2008-06-04
申请人： James F. Callahan , Jeffrey C. Boehm , Anthony William James Cooper , Stefano Livia , Paul Bamborough , Neysa Nevins , Zehong Wan , Beth A. Norton , Xichen Lin
发明人： James F. Callahan , Jeffrey C. Boehm , Anthony William James Cooper , Stefano Livia , Paul Bamborough , Neysa Nevins , Zehong Wan , Beth A. Norton , Xichen Lin
IPC分类号： A61K31/519 , A61K31/5377 , A61P3/00 , A61P27/00 , A61P11/00 , A61P9/00 , A61P25/00 , C07D471/04
CPC分类号： C07D487/04
摘要： Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
摘要翻译： 新型取代的2,4,8-三取代8H-吡啶并[2,3-d]嘧啶-7-酮的化合物和组合物，以及它们在CSBP / RK / p38激酶抑制剂治疗中的用途。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.068 秒)
